Benztropine Shortage: What Providers and Prescribers Need to Know in 2026

Benztropine mesylate remains a cornerstone anticholinergic for managing drug-induced extrapyramidal symptoms (EPS) and as adjunctive therapy in parkinsonism. Yet despite its long history and generic availability, clinicians and their patients continue to encounter supply disruptions that can compromise treatment continuity.

This briefing provides an up-to-date overview of the Benztropine supply landscape in 2026, the clinical implications of availability gaps, and actionable strategies for prescribers navigating these challenges.

Current Supply Status and Timeline

As of early 2026, Benztropine mesylate tablets are not listed on the FDA Drug Shortage Database as a national shortage. However, pharmacy-level stock-outs remain a persistent issue across the country. Key observations:

• Tablet supply (0.5 mg, 1 mg, 2 mg): Generally available through major wholesalers, but individual pharmacies — particularly large chain locations relying on automated inventory systems — report intermittent stock-outs. The 2 mg strength is most commonly affected.
• Injectable supply (1 mg/mL): Has experienced periodic shortages over the past several years due to the limited number of manufacturers producing sterile injectable anticholinergics. Hospital pharmacies and emergency departments may face intermittent gaps.
• Generic manufacturer landscape: Only a small number of companies (including Zydus, Amneal, and a few others) actively produce Benztropine. This concentrated market is vulnerable to disruptions when any single manufacturer encounters production issues.

Recent Timeline

• 2023-2024: Sporadic reports of pharmacy-level stock-outs, primarily affecting the injectable formulation and 2 mg tablets
• 2025: Continued intermittent supply disruptions. No official FDA shortage designation for tablets; injectable form listed intermittently
• 2026 (current): Supply has stabilized somewhat for oral tablets, but pharmacies in some regions still report difficulty maintaining consistent stock

Prescribing Implications

Supply disruptions present several clinical considerations for prescribers:

Treatment Interruption Risk

Patients who abruptly discontinue Benztropine may experience:

• Rebound or withdrawal symptoms, including cholinergic rebound (nausea, diaphoresis, agitation)
• Return of extrapyramidal symptoms, including acute dystonia
• Worsening of parkinsonian symptoms

It's critical to counsel patients about the importance of not stopping Benztropine without medical guidance, even if they can't find it at their pharmacy.

Strength Substitution

When the 2 mg strength is unavailable, prescribing two 1 mg tablets is a practical workaround. Consider proactively writing prescriptions with this flexibility in mind, or including a note allowing pharmacist substitution between strengths.

Proactive Prescribing

For patients on stable regimens, writing 90-day prescriptions can reduce the frequency of stock-out encounters and minimize treatment gaps. This is especially valuable for patients using mail-order pharmacy services.

Availability Picture: Where Patients Can Find Benztropine

Understanding pharmacy sourcing patterns can help you guide patients effectively:

• Independent pharmacies often have access to multiple wholesalers and may carry Benztropine when chains cannot
• Mail-order pharmacies typically maintain larger inventories and can provide 90-day supplies
• Hospital pharmacies may have stock of both oral and injectable forms through different distribution channels
• Medfinder for Providers enables clinicians to check pharmacy availability in real time, helping you direct patients to locations with current stock

Cost and Access Considerations

Benztropine's generic status keeps it affordable for most patients, but costs vary:

• Cash price: Approximately $25-$30 for 30 tablets without insurance
• With discount coupons: $4-$10 per month (GoodRx, SingleCare, etc.)
• Insurance coverage: Benztropine is on most formularies as a Tier 1 preferred generic with $0-$10 copays
• Patient assistance: No manufacturer-specific PAP exists (brand Cogentin is discontinued). Patients in financial hardship should be directed to NeedyMeds or RxAssist for generic assistance programs

For patients who face financial barriers, refer to our patient-facing guide on saving money on Benztropine.

Tools and Resources for Providers

Several resources can help you manage Benztropine availability for your patients:

• Medfinder Provider Tools: Real-time pharmacy stock checker — direct patients to pharmacies that have Benztropine in stock
• FDA Drug Shortage Database: Monitor official shortage status at accessdata.fda.gov
• ASHP Drug Shortage Resource Center: Clinical guidance on managing therapeutic substitutions during shortages

Therapeutic Alternatives

When Benztropine is unavailable, the following substitutions are supported by clinical evidence:

1. Trihexyphenidyl (Artane) — Most similar pharmacologic profile. 2-5 mg two to three times daily. More stimulating; use caution in patients prone to anxiety or insomnia. Higher cognitive side effect risk in elderly.
2. Diphenhydramine (Benadryl) — 25-50 mg every 6-8 hours. Useful for acute dystonia. More sedating. Shorter duration of action requires more frequent dosing.
3. Biperiden (Akineton) — 2 mg one to three times daily. More selective M1 antagonist. Less commonly stocked in U.S. pharmacies.
4. Procyclidine (Kemadrin) — 2.5-5 mg three times daily. Similar efficacy. Less widely available.

For additional detail on these alternatives, see our clinical overview: Alternatives to Benztropine.

Looking Ahead

The structural factors driving Benztropine supply challenges — concentrated generic manufacturing, low profit margins, and aging infrastructure — are unlikely to resolve quickly. Prescribers can mitigate impact by:

• Proactively discussing backup plans with patients
• Writing 90-day prescriptions when clinically appropriate
• Maintaining familiarity with therapeutic alternatives and dosing equivalencies
• Using tools like Medfinder to help patients locate in-stock pharmacies

The FDA's ongoing efforts to streamline generic drug approvals and incentivize manufacturing of essential generics may eventually improve the supply landscape, but in the meantime, proactive clinical management remains the best defense against treatment interruptions.

Final Thoughts

Benztropine supply challenges in 2026 represent a familiar pattern in the generic drug market: a critical medication with limited manufacturers and thin economics. For prescribers, the key is preparation — knowing the alternatives, understanding the cost landscape, and having tools ready to help patients find their medication quickly.

Explore Medfinder for Providers and share our patient resources: How to Find Benztropine in Stock and Benztropine Shortage Update for Patients.